The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.
Nadia Harbeck
No relevant relationships to disclose
Seock-Ah Im
Honoraria - LUX Korean Investigator meeting presentation
Research Funding - Az-KCSG Fellowship research fund
Chiun-Sheng Huang
No relevant relationships to disclose
Young-Hyuck Im
No relevant relationships to disclose
Binghe Xu
No relevant relationships to disclose
Sara A. Hurvitz
Research Funding - Boehringer Ingelheim
Keun-Seok Lee
No relevant relationships to disclose
Jin-Hee Ahn
No relevant relationships to disclose
Ajay O. Mehta
No relevant relationships to disclose
Rajender Singh Arora
No relevant relationships to disclose
Qiang Sun
No relevant relationships to disclose
Shukui Qin
No relevant relationships to disclose
Linu Abraham Jacob
No relevant relationships to disclose
Jacek Jassem
No relevant relationships to disclose
Elzbieta Staroslawka
No relevant relationships to disclose
Jozef Sufliarsky
No relevant relationships to disclose
Marek Wojtukiewicz
No relevant relationships to disclose
Annick Lahogue
Employment or Leadership Position - Boehringer Ingelheim
Martina Maria Uttenreuther-Fischer
Employment or Leadership Position - Boehringer Ingelheim
Martine J. Piccart-Gebhart
Consultant or Advisory Role - Boehringer Ingelheim; GlaxoSmithKline; Roche
Honoraria - Boehringer Ingelheim; GlaxoSmithKline; Roche